Mizuho Securities USA LLC Has $3.18 Million Stock Holdings in ResMed Inc. (NYSE:RMD)

Mizuho Securities USA LLC grew its position in ResMed Inc. (NYSE:RMD - Free Report) by 46.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 13,913 shares of the medical equipment provider's stock after purchasing an additional 4,385 shares during the period. Mizuho Securities USA LLC's holdings in ResMed were worth $3,182,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in RMD. Thrivent Financial for Lutherans lifted its holdings in shares of ResMed by 12.2% during the 3rd quarter. Thrivent Financial for Lutherans now owns 6,952 shares of the medical equipment provider's stock worth $1,697,000 after acquiring an additional 755 shares during the period. Quest Partners LLC increased its position in shares of ResMed by 472.5% during the third quarter. Quest Partners LLC now owns 1,872 shares of the medical equipment provider's stock worth $457,000 after acquiring an additional 1,545 shares in the last quarter. Intech Investment Management LLC acquired a new position in ResMed during the 3rd quarter worth approximately $244,000. Pacer Advisors Inc. raised its holdings in ResMed by 23.0% during the third quarter. Pacer Advisors Inc. now owns 29,347 shares of the medical equipment provider's stock worth $7,164,000 after acquiring an additional 5,483 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in ResMed by 1.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 924,047 shares of the medical equipment provider's stock worth $225,578,000 after buying an additional 13,985 shares during the last quarter. Institutional investors own 54.98% of the company's stock.

Remove Ads

Analyst Ratings Changes

A number of analysts have recently weighed in on RMD shares. KeyCorp upped their price target on shares of ResMed from $266.00 to $280.00 and gave the stock an "overweight" rating in a report on Friday, January 31st. Piper Sandler upped their price objective on shares of ResMed from $252.00 to $260.00 and gave the company a "neutral" rating in a research note on Friday, January 31st. JPMorgan Chase & Co. raised their price objective on shares of ResMed from $270.00 to $286.00 and gave the stock an "overweight" rating in a research report on Friday, January 31st. The Goldman Sachs Group began coverage on ResMed in a research report on Thursday, January 16th. They issued a "buy" rating for the company. Finally, StockNews.com raised shares of ResMed from a "hold" rating to a "buy" rating in a research report on Tuesday. One analyst has rated the stock with a sell rating, five have issued a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $246.83.

Insider Activity

In other news, CEO Michael J. Farrell sold 8,009 shares of the firm's stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $229.20, for a total transaction of $1,835,662.80. Following the completion of the transaction, the chief executive officer now owns 455,472 shares in the company, valued at approximately $104,394,182.40. This trade represents a 1.73 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Kaushik Ghoshal sold 9,113 shares of ResMed stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $235.40, for a total transaction of $2,145,200.20. Following the transaction, the insider now owns 9,725 shares in the company, valued at approximately $2,289,265. The trade was a 48.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 38,940 shares of company stock valued at $9,164,385 in the last 90 days. 0.71% of the stock is currently owned by insiders.

ResMed Stock Up 0.3 %

RMD stock traded up $0.74 during mid-day trading on Thursday, reaching $222.62. The company had a trading volume of 484,081 shares, compared to its average volume of 950,961. The firm has a fifty day simple moving average of $234.39 and a 200 day simple moving average of $238.55. The company has a market capitalization of $32.69 billion, a price-to-earnings ratio of 26.28, a price-to-earnings-growth ratio of 1.53 and a beta of 0.74. ResMed Inc. has a fifty-two week low of $172.19 and a fifty-two week high of $263.05. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.29 and a current ratio of 3.33.

ResMed (NYSE:RMD - Get Free Report) last posted its quarterly earnings data on Thursday, January 30th. The medical equipment provider reported $2.43 EPS for the quarter, beating analysts' consensus estimates of $2.29 by $0.14. ResMed had a net margin of 25.34% and a return on equity of 26.17%. Analysts forecast that ResMed Inc. will post 9.47 earnings per share for the current fiscal year.

ResMed Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 13th were paid a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a dividend yield of 0.95%. The ex-dividend date was Thursday, February 13th. ResMed's dividend payout ratio is presently 25.03%.

ResMed Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.